KANSAS CITY, Kan., April 14, 2023 (GLOBE NEWSWIRE) — Cingulate Inc. CINGa biopharmaceutical company leveraging its proprietary Precision Timed Release™ (PTR™) drug delivery technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that Chairman and CEO Shane J. Schaffer will be attending a Benzinga All Access will be held on Tuesday, April 18, 2023 at 10 a.m. CST.

The discussion will address the current unmet need in Attention Deficit Hyperactivity Disorder (ADHD) and the expansion of Cingulate’s PTR platform into the area of ​​anxiety therapy.

dr Schaffer will also provide a corporate overview, summarizing Cingulate’s recent clinical and business updates.

The event can be followed live on the Benzinga YouTube channel. Gasoline All Accessand will also be available on the Cingulate website at cingulate.com/investors.

About Cingulate^®
Cingulate Inc. CING, is a biopharmaceutical company using its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequent diagnosed diseases characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. With an initial focus on the treatment of Attention Deficit Hyperactivity Disorder (ADHD), Cingulate is identifying and evaluating additional therapeutic areas where PTR technology can be used to develop future product candidates, including the treatment of anxiety disorders.

Cingulate is headquartered in Kansas City. For more information visit cingulate.com

Investor Relations
Thomas Dalton
Vice President, Investor & Public Relations, Cingulate
TDalton@cingulate.com
913-942-2301

Matt Kreps
Darrow Associates
mkreps@darwir.com
214-597-8200

Media Relations
Melissa Weible
Elixir Health Public Relations
mweible@elixirhealthpr.com
201-723-5805